Truist lowered the firm’s price target on Allogene Therapeutics (ALLO) to $10 from $14 and keeps a Buy rating on the shares. The company reported Q1 earnings, announcing delays in its clinical trials to both ALPHA3 and ALLO-329, the analyst tells investors in a research note. This is “not optimal”, though the fact that Allogene was operationalizing non-traditional/community sites “buys them a hall pass”, Truist added, further noting that the firm does not see the delay as a negative indicator for ALPHA3.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer
- Allogene Therapeutics price target lowered to $9 from $12 at Baird
- Buy Rating Affirmed for Allogene Therapeutics Amid Strategic Developments and Financial Strength
- Allogene Therapeutics price target lowered to $7 from $9 at Piper Sandler
- Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential